NCT00001053View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 1996

Conditions
HIV Infections
Interventions
BIOLOGICAL

HIV p17/p24:Ty-VLP

BIOLOGICAL

Aluminum hydroxide

Trial Locations (1)

14642

Univ. of Rochester AVEG, Rochester

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001053 - A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects | Biotech Hunter | Biotech Hunter